Content area

Abstract

PrEP is an HIV prevention option that could benefit substance-involved women, a high-risk population with low PrEP uptake. Little is known about their interest in PrEP. This qualitative study used in-depth interviews to examine PrEP willingness, barriers, and facilitators among 16 women in outpatient psychosocial substance use treatment, methadone, and/or harm reduction/syringe programs in NYC. All expressed willingness to use PrEP, but only during periods of perceived risk. Women perceived themselves to be at high risk for HIV when engaging in active substance use and/or transactional sex. They perceived themselves to be at low risk and therefore unmotivated to take PrEP when abstinent from these activities. Paradoxically, a major barrier to using PrEP was anticipated interference from substance use and transactional sex, the very same activities that create a perception of risk. Facilitators of PrEP use included perceptions of it as effortless (as opposed to barrier methods during sex) and effective, safe, and accessible. Other barriers included fear of stigma and doubts about adhering daily. Recommendations for best PrEP implementation practices for substance-involved women included tailored and venue-specific PrEP information and messaging, PrEP discussion with trusted medical providers, and on-site PrEP prescription in substance use treatment and harm reduction programs.

Alternate abstract:

Resumen

PrEP es una opción de prevención de VIH que puede beneficiar a las mujeres que consumen sustancias, una población de alto riesgo con baja aceptación de la PrEP, pero poco se sabe de su interés en la PrEP. Este estudio cualitativo utilizó entrevistas para examinar el interés en tomar la PrEP y las barreras y los facilitadores del uso de la PrEP entre 16 mujeres en tratamiento por el uso de sustancias en clínicas ambulatorias, clínicas metadonas, o programas de reducción de daños en la ciudad de Nueva York, Estados Unidos. Todas las participantes expresaron su disposición a usar PrEP, pero solo durante períodos de riesgo percibido (por ejemplo, tiempos de uso de sustancias activas y/o sexo transaccional). Paradójicamente, una barrera importante para el uso de PrEP fue la interferencia anticipada por el uso de sustancias y el sexo transaccional, las mismas actividades que crean una percepción de riesgo. Los facilitadores incluyeron percepciones de PrEP como sin esfuerzo durante las relaciones sexuales, efectiva, segura, y accesible. Otras barreras incluyeron el miedo del estigma y dudas sobre la adherencia diaria. Las recomendaciones para las mejores prácticas de implementar la PrEP para mujeres que consumen sustancias incluyeron información y mensajes de PrEP personalizados y específicos del lugar, discusión de PrEP con proveedores médicos confiables, y prescripción de PrEP en el sitio en programas de tratamiento y reducción de daños por uso de sustancias.

Details

Title
A Qualitative Study of Barriers and Facilitators of PrEP Uptake Among Women in Substance Use Treatment and Syringe Service Programs
Author
Tross, Susan 1   VIAFID ORCID Logo  ; Spector, Anya Y. 2 ; Ertl, Melissa M. 1 ; Berg, Hayley 3 ; Turrigiano, Eva 4 ; Hoffman, Susie 5 

 Columbia University Irving Medical Center, HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675) 
 City University of New York, Department of Human Services, Stella and Charles Guttman Community College, New York, USA (GRID:grid.212340.6) (ISNI:0000000122985718) 
 Albert Einstein College of Medicine, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997) 
 New York State Psychiatric Institute, New York, USA (GRID:grid.413734.6) (ISNI:0000 0000 8499 1112) 
 Columbia University Irving Medical Center, HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Columbia University Mailman School of Public Health, Department of Epidemiology, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729) 
Pages
1162-1172
Publication year
2023
Publication date
Apr 2023
Publisher
Springer Nature B.V.
ISSN
10907165
e-ISSN
15733254
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2789883335
Copyright
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.